The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2026

Filed:

Dec. 18, 2020
Applicant:

Cambridge Enterprise Limited, Cambridge, GB;

Inventors:

Tony James Wu, Cambridge, GB;

Michael Gill, Cambridge, GB;

Martin Miller, Cambridge, GB;

Oliver Cast, Cambridge, GB;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/7068 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/7068 (2013.01); A61P 35/00 (2018.01); G01N 33/57484 (2013.01); G01N 2800/52 (2013.01);
Abstract

The invention provides a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of pancreatic cancer, in particular a CCR1 antagonist, for example in combination with one or more further therapeutic agents effective as anti-tumour agents in the treatment of pancreatic cancer. Such an anti-tumour agent may be a chemotherapeutic agent selected from Gemcitabine, Fluorouracil (5-FU), Capecitabine, FOLFIRINOX (Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride and Oxaliplatin), Nab-paclitaxel (Abraxane®) and combinations thereof. An immuno-oncology agent (e.g. a PD-1 inhibitor and/or a PD-L1 inhibitor) may also favourably be used with the CCR1 antagonist.


Find Patent Forward Citations

Loading…